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Abstract
Members of the recently introduced fungal genus Rasamsonia
(formerly included in the Geosmithia genus) have been described as
emerging pathogens in immunosuppressed hosts or patients with
cystic fibrosis (CF). Rasamsonia species have often been misiden-
tified as Penicillium or Paecilomyces because of similar morpholog-
ical characteristics. We validated a commercially available
real-time PCR assay (PrimerdesignTM, UK) for accurate detection
of species from the Rasamsonia argillacea complex. First, we tested
this assay with a collection of 74 reference strains and clinical
isolates and then compared the PCR with cultures of 234
respiratory samples from 152 patients with CF from two
University Hospitals in Germany and France. The assay reliably
detected the three main species within the Rasamsonia argillacea
species complex (R. argillacea, R. piperina, R. aegroticola), which are
typically encountered in CF patients. The limit of DNA detection
was between 0.01 and 1 pg/lL. Analysis of the DNA extracts
from respiratory specimens of CF patients revealed that four out
of the 153 patients studied (2.6%) were colonized with R. arg-
illacea species complex. Two species from the R. argillacea
complex grew in the parallel cultures from the same patients.
In one patient the PCR was positive 5 months before culture.
The real-time PCR assay is a sensitive and specific method for
detecting the three most important species of the R. argillacea
species complex encountered in the CF context. Detection of
these emerging pathogens in respiratory secretions from CF
patients by this novel assay may increase our understanding of
the occurrence and epidemiology of the R. argillacea species
complex.
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Introduction
Cystic fibrosis (CF) is an autosomal recessive disease caused
by mutations in the cystic fibrosis transmembrane regulator
(CFTR) gene. This disease occurs in ~ 1 in 2500 live births in
the Caucasian population [1] and affects exocrine glands of
several organs, particularly the lungs, where it results in the
production of thick and sticky mucus. In the lower airways, this
provides an ideal breeding ground for many microorganisms
and facilitates recurrent respiratory infections with viruses,
bacteria and fungi [2]. Aspergillus fumigatus is the most
prevalent filamentous fungus in the respiratory tract of CF
patients [3]. It has been reported that CF patients chronically
colonized with A. fumigatus have a decreased lung function,
more frequent exacerbations and more prominent radiological
abnormalities than non-colonized or transiently colonized CF
patients [4]. Besides Aspergillus spp., Scedosporium/Pseudalle-
scheria species were reported ranking usually second among
the filamentous fungi colonizing the CF airways [5–7]. Also
other moulds like Aspergillus terreus or Exophiala dermatitidis
may also be encountered in the CF context, with prevalence
rates varying from one country to another. However, the
clinical relevance of the airway colonization by non-A. fumig-
atus moulds is not clearly established. Recently, a new species
complex, R. argillacea, has been described as emerging in
patients with CF [8,9].
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Rasamsonia spp. are filamentous thermophilic fungi com-
monly isolated from hot environments [10,11]. The species
R. argillacea was first described by Stolk et al. in 1969 under
the name Penicillium argillaceum [12]. Ten years later, Pitt
renamed this species Geosmithia because of its morphological
characteristics [13]. In 1999, this fungus was described for the
first time in a French CF patient as P. emersonii based on
morphological characteristics [14]. In 2009, researchers
reported the first isolation of this organism from a dissemi-
nated infection in a German Shepherd dog [15]. Recently,
Houbraken et al. showed that G. argillacea and other Geosmi-
thia species form a distinct clade within the Trichocomaceae
[16] and proposed the new genus Rasamsonia. In addition,
phylogenetic analyses of the internal transcribed spacer, partial
b-tubulin and calmodulin sequences revealed that R. argillacea
is a species complex comprising four distinct species [16].
Re-identification of nine published CF isolates from France
revealed three cases of R. argillacea, four colonizations with
R. aegroticola, and two cases of R. piperina [8,16]. In contrast,
R. eburnea has also been found in sterile fluids of human origin
but not in patients with CF [16].
In the present study, we validated a novel real-time PCR
assay (PrimerDesignTM, Southampton, UK) for the detection of
the three species of the R. argillacea species complex typically
found in CF patients and compared the results of this assay
with cultures of reference strains. In addition, we evaluated the
performance of this novel PCR assay by testing respiratory
samples from patients with CF.
Methods
Culture isolates
In order to assess the specificity of the real-time PCR assay, 39
reference strains and clinical isolates from non-Rasamsonia
species from the fungal and bacterial culture collection of the
Institute of Medical Microbiology (IMMI), University Hospital
Essen, Essen, Germany were analysed (Table 1).
Twenty-two reference strains belonging to the genus
Rasamsonia were obtained from the collection of the Centra-
albureau voor Schimmelcultures (CBS)-Fungal Biodiversity
Centre, Utrecht, the Netherlands (DTO) (Table 2). Thirteen
clinical isolates were collected from clinical specimens sub-
mitted to three German university hospitals in 2010 and 2011
(Hannover, Cologne, Essen) (Table 2).
Identification of clinical isolates
In addition to macro- and micromorphological features, the
identification of clinical isolates was based primarily on
sequence analysis of the internal transcribed spacer (ITS) 1
and two regions of the fungi, as was previously described for
Scedosporium spp. [17].
DNA extraction of cultured isolates
All fungal reference strains and clinical isolates were grown on
malt extract agar (Oxoid, Wesel, Germany) at 35°C for
5 days. An agar block of approximately 1 cm2 in size was
transferred to a 1.5-mL reaction tube and homogenized with a
micropestle. The grounded mycelium–agar mixture was incu-
bated at 56°C for 60 minutes with 500 lL of extraction buffer
[18] containing 0.2 M Tris–HCl, 0.5 M sodium chloride,
0.01 M EDTA (pH 8.0), 1% SDS and 1 mg/mL proteinase K.
After the addition of an equal volume of phenol (Roti-Phenol,
Roth, Germany), the mixture was vigorously shaken and
centrifuged at 20 000 g for 3 min. The supernatant containing
the DNA was transferred to a new reaction tube and mixed
with an equal volume of chloroform. After centrifugation at
TABLE 1. Non-Rasamsonia strains (n = 39) tested for




Aspergillus cf. tamarii ATCC 64841
Aspergillus flavus CBS 113.49
Aspergillus fumigatus NCPF2140
A. fumigatus CBS 133.61
A. fumigatus CBS 154.89
Aspergillus nidulans CBS 100.20
Aspergillus niger CBS 112.30
Aspergillus brasiliensis CBS 733.88
Aspergillus terreus CBS 469.81
Aspergillus versicolor IMMI F81
Candida albicans ATCC 44374
Candida glabrata DSM 70614
Candida guilliermondii ATCC 90877
Candida kefyr DSM1195
Candida krusei DSM 70075
Candida parapsilosis ATCC 22019
Candida tropicalis ATCC 750
Exophiala dermatitidis CBS 120550
Fusarium solani IMMI 1650
Paecilomyces lilacinus IMMI 1900
Penicillium citrinum IMMI 1945
Penicillium notatum IMMI 2013
Pseudallescheria boydii FMR 84
Rhizomucor microsporus IMMI 1672
Rhizomucor pusillus IMMI 1671
Scedosporium apiospermum IMMI F71
Scedosporium prolificans IMMI F78
Bacteria
Enterococcus faecalis ATCC 29212
Enterococcus faecium DSM 13590
Staphylococcus aureus ATCC 43300
Staphylococcus epidermidis DSM 1789
Streptococcus pyogenes DSM 11728
Acinetobacter baumannii IMMI 150
Enterobacter cloacae IMMI 253
Haemophilus influenzae DSM 9999
Klebsiella pneumoniae IMMI 251
Legionella pneumophila ATCC 33152
Proteus mirabilis DSM 4479
Serratia marcescens ATCC 13880
Mycobacterium tuberculosis ATCC 27294
Mycobacterium avium DSM 44156
NCPF, national collection of pathogenic fungi; CBS, culture collection of the
CBS-Fungal Biodiversity Centre, Utrecht, the Netherlands; ATCC, American Type
Culture Collection; IMMI, internal fungal collection of the Institute of Medical
Microbiology, University Hospital Essen, Essen, Germany; FMR, Facultat de
Medicina, Reus, Spain.
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20 000 g for 3 min, 0.2 volume of 5 M ammonium acetate
and 0.7 volume of 2-propanol were added to the supernatant.
The solution was incubated at room temperature for 10 min
and then centrifuged at 20 000 g for 10 min. The resulting
pellet of DNA was washed with 500 lL of 70% ethanol,
centrifuged at 20 000 g for 2 min, and air-dried. The dry pellet
was re-suspended in 100 lL of Tris-EDTA (TE) buffer (pH
8.0) and stored at 4°C until use. DNA concentration was
measured with a Nanodrop 1000 spectrophotometer
(Thermo Scientific, Dreieich, Germany).
DNA extraction of respiratory specimens from CF patients
Samples were prepared with the MycXtra DNA preparation
kit (Myconostica, Cambridge, UK) according to the manufac-
turer’s instructions. To homogenize the respiratory samples,
all specimens were pre-treated with an equal volume of freshly
prepared Sputasol (Oxoid, UK) at 37°C for 15–30 min. The
DNA from 1 mL of homogenized sputum was extracted. The
elution volume was 80 lL in TE buffer; for PCR, tenfold serial
dilution was again used.
Primers and probe design
Primers and probe were designed by PrimerDesignTM Ltd.
(Southampton, UK). Because of copyright issues, the
sequences cannot be provided. All primers and probes bound
within a 499-bp-long partial sequence of the calmodulin (CAL)
gene of Rasamsonia argillacea (CBS 128787, GenBank accession
number JF417504). The final amplification product was 87 bp
in length.
Real-time PCR assay
Amplification was performed on a Rotor-Gene 6000 thermal
cycler in a final volume of 20 lL (Path-G. argillacea and Path-G.
argillacea-standard, respectively (http://www.genesig.com/
products/9254). The reaction mixture consisted of 10 lL of
29 Precision MasterMix (PrimerDesignTM), 1 lL of R. argilla-
cea pimer/probe mix, 1 lL of internal extraction control
primer/probe mix, 3 lL of nuclease-free water, and 5 lL of
sample or fungal DNA. The internal extraction control primer/
probe mix was substituted by nuclease-free water whenever
extracted DNA of culture strains was amplified. Specific
amplification of the CAL gene was monitored in the FAM
channel of the Rotor-Gene 6000 instrument, whereas inhibi-
tion control was monitored in the JOE channel.
Assay detection limit
Serial ten-fold dilutions of the positive control (2 9 105 to
2 9 100 copies/lL of the CAL gene) were incorporated in the
PCR kit. Ten-fold serial dilutions of DNA extracts from
reference strains were made in TE buffer (pH 8.0). The
detection limit was determined by comparing the final cycle
threshold values of the sample dilutions with a standard curve
established with dilutions of the positive control.
Study cohort and mycological examination of respiratory
samples from CF patients
In total, 214 samples from 138 CF patients (one to four
samples per patient) attending the University Hospital Essen
and the Clinic of the Ruhr, West German Lung Centre, Essen,
Germany, in 2012 were tested for the presence of DNA from
Rasamsonia species as mentioned above. For culturing, 100 lL
TABLE 2. Rasamsonia culture isolates (n = 35) used for val-
idation of the Rasamsonia argillacea species complex PCR
Species Strain no. Source of isolation Origin
Rasamsonia reference strains (n = 22)
R. aegroticola DTO 049D4 Sputum from
CF patient
UK






R. argillacea CBS 128787 Heat-treated
fruit concentrate
The Netherlands
R. argillacea DTO 097E4 Mine tip UK
R. argillacea DTO 097E5 Air UK
R. argillacea DTO 097E7 Unknown source UK
R. brevistipitata DTO 25H2 Indoor environment
of school
Germany
R. brevistipitata DTO 26B1 Indoor environment
of school
Germany
R. cylindrospora DTO 138F7 Sputum The Netherlands
R. cylindrospora DTO 138F8 Culture contaminant UK
R. eburnea DTO 045I3 Contaminant of
blood culture
UK
R. eburnea DTO 049D9 Peritoneal dialysis
fluid
UK
R. piperina DTO 076F1 Seed of Piper nigrum Spain
R. piperina DTO 097E6 Wood chips of
Picea abis
Sweden
R. piperina DTO 097E9 Bronchial washing Canada
R. piperina DTO 138F5 Necropsy thoracic
vertebra of dog
USA
R. piperina DTO 138F6 Necropsy thoracic
vertebra of dog
USA
R. piperina DTO 139F9 Air Germany
R. piperina DTO 138G1 Wood chips of
Picea abies
Sweden
R. piperina DTO 138G2 Wood chips of
Picea abies
Sweden
R. piperina DTO 138G3 Seed of Piper nigrum Spain
R. piperina CBS 128034 Necropsy ex vertebra
of canine
USA
Rasamsonia clinical isolates (n = 13)
R. aegritocola IMMI 1419 BAL from lung
transplant recipient
Germany




R. aegroticola IMMI 1869 BAL from lung transplant
recipient
Germany
R. aegroticola IMMI 1896 Sputum from CF patient Germany
R. aegroticola IMMI 2824 Sputum from CF patient Germany
R. argillacea IMMI 1764 BAL from bone marrow
transplant recipient
Germany
R. argillacea IMMI 1862 Sputum from CF patient Germany
R. argillacea IMMI 1870 Eczema of integument Germany
R. argillacea IMMI 1881 Sputum from CF patient Germany
R. argillacea IMMI 1893 Sputum from CF patient Germany
R. argillacea IMMI 1894 Sputum from CF patient Germany
R. argillacea IMMI 1895 Sputum from CF patient Germany
R. piperina IMMI 1464 Sputum from CF patient Germany
CBS, culture collection of the CBS-Fungal Biodiversity Centre, Utrecht, The
Netherlands; DTO, internal culture collection of the CBS-Fungal Biodiversity
Centre; IMMI, internal fungal collection of the Institute of Medical Microbiology,
University Hospital Essen, Essen, Germany; CF, cystic fibrosis; BAL, broncho-alve-
olar lavage.
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of the sputasol-pretreated respiratory samples were inocu-
lated on malt agar (Oxoid) and incubated aerobically at 36°C
for 2 days and then at 22°C for an additional 8 days.
In addition, 20 sputum samples from 15 CF patients
followed up in Angers University Hospital, Angers, France,
were also analysed. Mycological examination of these samples
performed in parallel to the PCR assay consisted of the
inoculation of 10-lL aliquots of the digested samples on
CHROMagar Candida (Becton-Dickinson, Franklin, NJ, USA),
yeast extract-peptone-dextrose agar (YPDA) supplemented
with chloramphenicol and gentamicin (Becton-Dickinson),
Dichloran-rose bengale-chloramphenicol agar (DRBC), YPDA
supplemented with chloramphenicol and cycloheximide, and
erythritol agar. Incubation was carried out at 37°C for
2 weeks, except for the last two culture media, which were
incubated at 25°C. Mould isolates were identified by cultural
and microscopic morphological characteristics.
Results
Validation of the real-time PCR assay on cultured strains or
isolates
The multiplex PCR assay did not demonstrate cross-reactivity
with any of the 39 fungal or bacterial isolates shown in Table 1.
The primer specificity of the assay was demonstrated by the
fact that the amplification products from real-time PCR of six
Rasamsonia species produced species-specific band sizes
(87 bp) in a gel for all four species from the R. argillacea
species complex (R. argillacea, R. piperina, R. aegroticola and
R. eburnea) (Fig. 1a). DNA from R. brevistipitata and R. cylind-
rospora could be amplified, but showed no specific band size of
87 bp.
In contrast, DNA of R. eburnea was amplified by the
primer set, but the probe of the assay was not able to
detect this species in the FAM channel. The performance of
the real-time PCR assay, using serial dilutions from the
standard and from the extracted DNA of the three main
species in the R. argillacea complex, is depicted in Fig. 2. The
detection limit was 7.51 copies/lL for R. aegroticola, 2.51
copies/lL for R. piperina and 1.27 copies/lL for R. argillacea
(~0.01, 0.1 and 1 pg/lL of DNA). The assay was validated
with a collection of 22 reference strains and 13 clinical
isolates (Table 2). All isolates of the three previously
mentioned Rasamsonia species were detected, whereas
reference strains of R. eburnea, R. brevistipitata and R. cylind-
rospora were not detected. In summary, the PCR assay is
able to detect the three Rasamsonia species encountered in
CF (R. argillacea, R. piperina, R. aegroticola) from the R. argill-
acea species complex.
Validation of the real-time PCR assay with respiratory
samples from CF patients
First, 214 respiratory secretions from 138 patients with CF
were analysed to study the diagnostic utility of the R. argillacea
species complex real-time PCR assay. No inhibition of PCR
was observed in any sample.
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6
100 bp 
(b)(a)
FIG. 1. Results of the real-time PCR assay. (a) Results obtained with
DNA extracts from pure cultures of reference strains: Lane 1, 50-bp
DNA marker; Lane 2, Rasamsonia argillacea reference strain; Lane 3,
R. eburnea; Lane 4, R. aegroticola; Lane 5, R. piperina; Lane 6, R. argill-
acea; Lane 7. R. cyclindrospora; Lane 8, R. brevistipitata; Lane 9, 50-bp
DNA marker. (b) Results obtained with DNA extracts from sputum
samples of positive samples from patients with cystic fibrosis (CF):
Lane 1, 50-bp DNA marker; Lane 2, R. argillacea reference strain; Lane
3, sputum negative for R. argillacea complex; Lane 4, R. argillacea from
CF patient 1; Lane 5, R. aegroticola from CF patient 2; Lane 6, 50-bp
DNA marker.
FIG. 2. Amplification curves in the FAM channel for standards and
DNA extracts from species of the Rasamsonia argillacea species
complex demonstrating detection of R. aegroticola, R. argillacea and R.
piperina. A tenfold serial dilution of the internal positive control
(2 9 105/lL to 2 9 100/lL) was used as standard.
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For two patients, the results of the DNA assay were
positive for R. argillacea complex DNA, and the assay gener-
ated an amplicon of the correct size (c.87 bp) in the gel
(Fig. 1b). Samples from one patient repeatedly tested were
positive for R. argillacea by PCR, and R. argillacea was also
detected by culture. The culture of the second PCR-positive
sample was initially negative, but the patient became positive
for R. aegroticola 5 months later (Table 3).
To verify the results from this first single-centre approach,
20 sputa from 15 French CF patients were blindly analysed for
the presence of R. argillacea complex DNA. Three samples
from two patients were positive by PCR. In one patient,
cultures from two successive sputum samples were positive
for R. argillacea complex (Table 3). The clinical and microbi-
ological characteristics of all four CF patients with positive
PCR for R. argillacea species complex are shown in Table 4.
Discussion
Here we describe the validation of a new, commercially
available real-time PCR assay for the detection of three species
from the R. argillacea complex. This assay was validated with
both a collection of reference strains and clinical isolates of
Rasamsonia species and was capable of detecting all three
relevant species that are encountered in CF (R. argillacea,
R. piperina and R. aegroticola). No other unrelated fungal or
bacterial species were positive by the PCR assay. Of the clinical
samples, two German CF patients were PCR-positive for the
Rasamsonia species complex; one was initally positive for
R. argillacea by culture whereas the culture from the other
patient became positive for R. aegroticola 5 months later.
Likewise, two of the 15 CF patients tested from France were
found to be PCR-positive, but cultures detected the presence
of the fungus for only one of them. These results may indicate
that the PCR is more sensitive than culture.
Rasamsonia spp., formerly named Geosmithia spp., have been
described as emerging pathogens in patients with CF [8,9]. In
total, four studies from France and the United Kingdom have
reported the colonization of 18 CF patients by the R. argillacea
species complex [8,9,19,20]. However, the presence or
persistence of these fungi was associated with a decrease in
lung function or with pulmonary exacerbation in only one case
[20]. Our knowledge about the relevance and role of this
fungus in CF is still limited because this pathogen has been only
recently described, and data about its real prevalence in the CF
population are lacking. The prevalence of the R. argillacea
species complex in CF patients screened by the PCR assay in
the present two-centre study was 2.6% (4/153). Recently, a
single-centre study from Austria demonstrated that R. argilla-
cea was found in five of 113 (4.4%) CF patients by culturing
homogenized sputum samples [21].
In agreement with previous results, we found that coloni-
zation with R. argillacea complex was not associated with
clinical deterioration in three out of the four PCR-positive
patients. Conversely, a clinical and functional deterioration was
seen for patient 3 (Table 4), associated with the detection of
the R. argillacea species complex by culture, but cultures also
yielded numerous colonies of Exophiala dermatitidis.
When patients are immunocompromised (e.g. after lung
transplantation), the R. argillacea complex can be relevant for
CF patients, because it can cause invasive infections as
demonstrated by cases of disseminated R. argillacea infections
in patients with chronic granulomatous diseases or with
haematological malignancies [22–24]. Very recently, a case
report from the USA described the infection of a pulmonary
and aortic graft with R. argillacea in an immunocompetent
patient [25].
TABLE 3. Characteristics of the cystic fibrosis (CF) popula-









Mean age  SD, years (range) 26.6  10.1 (4–47) 17.1  9.3 (3–33)
Female (%) 61 (44.2) 10 (66.7)
Number of specimens 214 20
Specimens per CF patient
(range)
1.6 (1–4) 1.25 (1–4)
Specimens positive for the R. argillacea species complex
By the real-time PCR assay 4 3
By cultures 3 2
By both PCR and cultures 3 2
TABLE 4. Clinical and microbiological data of cystic fibrosis
(CF) patients with DNA detection of Rasamsonia argillacea
species complex
Patient 1 Patient 2 Patient 3 Patient 4
Age, years 18 37 23 7
Sex Male Female Female Female
F508 del
mutation




No No Yes Yes
CF-related
diabetes
No No No No
Listed for lung
transplantation
No No No No
FEV1 41% 30% 63% 80%
Clinical specimen
tested




Yes Yes No Yes
Aspergillus
fumigatus
Yes No Yes Yes
R. argillacea
complex
R. argillacea R. aegroticola Yes No
CF, cystic fibrosis; FEV1, forced expiratory volume in 1 seconds.
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All reports of infections with R. argillacea complex and a
recent review highlight the importance and relevance of
adequate identification of these species [25]. Identification of
Rasamsonia species is difficult because their phenotypic
and morphological characteristics are very similar to those
of other fungi, such as Penicillium and Paecilomyces species
[10,16,22,24]. The correct identification of the Rasamsonia
species complex is not only important for differentiation
from non-pathogenic fungi but is also crucial for therapeutic
aspects, because the susceptibility profile of Rasamsonia
species is different from that of many other moulds. Isolates
from the R. argillacea complex show high MICs for the
triazole drugs itraconazole, voriconazole and posaconazole,
and low MICs for the echinocandins such as caspofungin
and micafungin [8,16]. Therefore, an accurate identification
of this species complex is essential for minimizing the
delay in diagnosis and in the initiation of appropriate
antifungal therapy that results from difficulties in correct
identification.
It has been reported that molecular-based techniques such
as sequencing should be performed for species identification of
the R. argillacea complex in conjunction with conventional
mycological methods [16,26]. However, sequencing is only
available in specialized laboratories. PCR assays are established
techniques in most laboratories and offer an excellent
alternative tool for the detection of fungal DNA without
culture methods. In addition to their higher sensitivity, PCR
tests are more rapid than culture-based methods and allow the
direct detection of fungi in patient specimens.
The primers and probes were labelled by PrimerDesign Ltd
and we cannot provide the primer sequence because of
copyright issues. However, one advantage of the real-time
PCR assay described and validated by this study is that it is now
commercially available (http://www.genesig.com/products/
9254). Hence, all laboratories have access to this PCR assay.
Future studies can use this standardized PCR assay to detect
the R. argillacea species complex.
A limitation of the study is that the two study sites used
different culture methods and conditions for fungal detection.
In addition, the number of clinical specimens from the CF
patient population that were found positive for species of the
R. argillacea species complex was low, as this was only a
double-centre study, and only four patients were colonized or
infected with species of the R. argillacea complex.
In conclusion, the real-time PCR assay seems to be useful
for routine detection of the three Rasamsonia species
encountered in CF (R. argillacea, R. piperina, R. aegroticola).
This novel assay may increase our understanding of the
occurrence, aetiology and epidemiology of the R. argillacea
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